We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment
Read MoreHide Full Article
Stryker Corporation (SYK - Free Report) recently announced that it has completed the acquisition of SERF SAS, a France-based joint replacement company from Menix.
The acquisition of SERF SAS demonstrates Stryker’s commitment to orthopedic excellence and expands its worldwide range. Together with the SERF SAS team, Stryker aims to aid in advanced product innovation and customer satisfaction.
Price Performance
For the past six months, SYK’s shares have rallied 23.0% compared with the industry’s rise of 10.0%. The S&P 500 increased 19.9% in the same time frame.
Image Source: Zacks Investment Research
More on SERF SAS
The French company SERF SAS designs, produces and markets a variety of major joint replacement systems worldwide. Among the many creative ideas that SERF SAS has created since its establishment is the original Dual Mobility Cup.
SERF SAS comes from Menix, which comprises 3D digital solutions and advanced technology industries in the dental and orthopedic fields. Menix holds a dominant position in the French dual mobility and first intention stem markets within the orthopedic industry.
More on the Acquisition
Through the strengthening of its implant product line, this acquisition will likely expand Stryker's patient base by enhancing its worldwide joint replacement portfolio and augmenting its current position in France and throughout Europe. SERF SAS is recognized by healthcare professionals worldwide for its innovations in hip implants, including the invention of the original Dual Mobility Cup.
In December 2023, Stryker announced the execution of a bidding offer to Menix to acquire SERF SAS.
Industry Prospects
Per a report by Grand View Research, the global joint replacement market was valued at $17.1 billion in 2020 and is expected to witness a growth rate of 3.4% from 2021 to 2028.
The increase in the prevalence of orthopedic disorders, osteoporosis, osteoarthritis, and lower extremity conditions are some factors driving the market for joint replacement. The increasing incidence of chronic diseases like rheumatoid arthritis leads to a high demand for surgical interventions, which thereby propels growth of the joint replacement market.
Given the market potential for joint replacement, Stryker acquiring SERF SAS is likely to boost the company’s business in the European region and generate additional revenues.
Notable Development
Stryker recently announced the completion of its first shoulder arthroplasty surgery in Europe using its Blueprint Mixed Reality Guidance system, which aims to benefit shoulder arthroplasty surgeons.
Some other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Cencora, Inc. (COR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 58.3% compared with the industry’s 18.9% rise in the past year.
Cardinal Health, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 51.9% compared with the industry’s 3.2% rise in the past year.
Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 9.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.7%.
Cencora’s shares have rallied 51.5% compared with the industry’s 3.6% rise in the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment
Stryker Corporation (SYK - Free Report) recently announced that it has completed the acquisition of SERF SAS, a France-based joint replacement company from Menix.
The acquisition of SERF SAS demonstrates Stryker’s commitment to orthopedic excellence and expands its worldwide range. Together with the SERF SAS team, Stryker aims to aid in advanced product innovation and customer satisfaction.
Price Performance
For the past six months, SYK’s shares have rallied 23.0% compared with the industry’s rise of 10.0%. The S&P 500 increased 19.9% in the same time frame.
Image Source: Zacks Investment Research
More on SERF SAS
The French company SERF SAS designs, produces and markets a variety of major joint replacement systems worldwide. Among the many creative ideas that SERF SAS has created since its establishment is the original Dual Mobility Cup.
SERF SAS comes from Menix, which comprises 3D digital solutions and advanced technology industries in the dental and orthopedic fields. Menix holds a dominant position in the French dual mobility and first intention stem markets within the orthopedic industry.
More on the Acquisition
Through the strengthening of its implant product line, this acquisition will likely expand Stryker's patient base by enhancing its worldwide joint replacement portfolio and augmenting its current position in France and throughout Europe. SERF SAS is recognized by healthcare professionals worldwide for its innovations in hip implants, including the invention of the original Dual Mobility Cup.
In December 2023, Stryker announced the execution of a bidding offer to Menix to acquire SERF SAS.
Industry Prospects
Per a report by Grand View Research, the global joint replacement market was valued at $17.1 billion in 2020 and is expected to witness a growth rate of 3.4% from 2021 to 2028.
The increase in the prevalence of orthopedic disorders, osteoporosis, osteoarthritis, and lower extremity conditions are some factors driving the market for joint replacement. The increasing incidence of chronic diseases like rheumatoid arthritis leads to a high demand for surgical interventions, which thereby propels growth of the joint replacement market.
Given the market potential for joint replacement, Stryker acquiring SERF SAS is likely to boost the company’s business in the European region and generate additional revenues.
Notable Development
Stryker recently announced the completion of its first shoulder arthroplasty surgery in Europe using its Blueprint Mixed Reality Guidance system, which aims to benefit shoulder arthroplasty surgeons.
Stryker Corporation Price
Stryker Corporation price | Stryker Corporation Quote
Zacks Rank & Other Stocks to Consider
SYK carries a Zacks Rank #2 (Buy) at present.
Some other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Cencora, Inc. (COR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 58.3% compared with the industry’s 18.9% rise in the past year.
Cardinal Health, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 51.9% compared with the industry’s 3.2% rise in the past year.
Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 9.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.7%.
Cencora’s shares have rallied 51.5% compared with the industry’s 3.6% rise in the past year.